Stock 688192 DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Equities

688192

CNE1000055W8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-27 pm EDT 		5-day change 1st Jan Change
40.9 CNY +0.64% Intraday chart for Dizal (Jiangsu) Pharmaceutical Co., Ltd. -2.90% -14.52%
May. 24 Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations CI
Apr. 29 Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 14,959 16,030 19,530 17,000 - -
Enterprise Value (EV) 1 14,959 16,030 19,530 17,000 17,000 17,000
P/E ratio -19.9 x -21.6 x -17.6 x -16.8 x -24.3 x -104 x
Yield - - - - - -
Capitalization / Revenue 1,454 x - 214 x 42.4 x 19.2 x 8.93 x
EV / Revenue 1,454 x - 214 x 42.4 x 19.2 x 8.93 x
EV / EBITDA - -23.2 x -18.4 x -17.4 x -26.8 x -127 x
EV / FCF - -23.7 x -19.5 x -13.8 x -21.4 x 300 x
FCF Yield - -4.22% -5.12% -7.27% -4.68% 0.33%
Price to Book 6.07 x 9.11 x 23.5 x -104 x -19.7 x -18.3 x
Nbr of stocks (in thousands) 404,183 407,160 408,151 415,653 - -
Reference price 2 37.01 39.37 47.85 40.90 40.90 40.90
Announcement Date 2/25/22 2/27/23 2/24/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 10.29 - 91.29 401.3 886.3 1,903
EBITDA 1 - - -692.4 -1,060 -979 -634.5 -134
EBIT 1 - -669.9 -735.7 -1,108 -1,014 -699.3 -164.5
Operating Margin - -6,512.85% - -1,213.31% -252.66% -78.9% -8.64%
Earnings before Tax (EBT) 1 - -669.9 -735.7 -1,108 -1,014 -699.3 -164.5
Net income 1 -586.6 -669.9 -736 -1,108 -1,014 -699.3 -164.5
Net margin - -6,512.85% - -1,213.42% -252.66% -78.9% -8.64%
EPS 2 -1.630 -1.860 -1.820 -2.720 -2.440 -1.683 -0.3950
Free Cash Flow 1 - - -677.2 -1,000 -1,235 -794.8 56.73
FCF margin - - - -1,095.44% -307.78% -89.67% 2.98%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 11/22/21 2/25/22 2/27/23 2/24/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - -677 -1,000 -1,235 -795 56.7
ROE (net income / shareholders' equity) - -37.8% -34.9% -85% -426% - -
ROA (Net income/ Total Assets) - - -30.5% -62.8% -73% -44.6% -15.1%
Assets 1 - - 2,414 1,764 1,390 1,570 1,089
Book Value Per Share 2 - 6.090 4.320 2.040 -0.3900 -2.080 -2.240
Cash Flow per Share 2 - -1.370 -1.480 - -2.630 -1.650 -
Capex 1 - - 73.8 32.1 104 117 76.5
Capex / Sales - - - 35.19% 25.98% 13.14% 4.02%
Announcement Date 11/22/21 2/25/22 2/27/23 2/24/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
40.9 CNY
Average target price
54 CNY
Spread / Average Target
+32.03%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. Stock Dizal (Jiangsu) Pharmaceutical Co., Ltd.
-14.52% 2.35B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.83% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.80% 105B
BIONTECH SE Stock BioNTech SE
-10.84% 22.71B
ARGENX SE Stock argenx SE
-1.69% 21.83B
GENMAB A/S Stock Genmab A/S
-10.23% 18.18B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.11% 16.01B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.62% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.53% 10.71B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 688192 Stock
  4. Financials Dizal (Jiangsu) Pharmaceutical Co., Ltd.